News | June 11, 2024
Abbott wins CE mark for dual-chamber leadless pacemaker
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Open a printable version of this pageEmail the URL of this page to a friend
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Subscribe To Our Newsletter & Stay Updated
